TRIPLE ANTICOAGULANT THERAPY INCLUDING NOVEL ANTICOAGULANTS (NOACS) AND DUAL ANTIPLATELET THERAPY (DAPT) IS ASSOCIATED WITH SIGNIFICANTLY INCREASED HEMORRHAGE RISK THAN DAPT ALONE
[...]there are no studies evaluating bleeding risk using triple therapy (including NOACs) vs. [...]we sought to evaluate bleeding risk with triple therapy including NOACs vs.
Gespeichert in:
| Veröffentlicht in: | Journal of the American College of Cardiology 2016-04, Vol.67 (13), p.546-546 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 546 |
|---|---|
| container_issue | 13 |
| container_start_page | 546 |
| container_title | Journal of the American College of Cardiology |
| container_volume | 67 |
| creator | Pattanshetty, Deepak Aneja, Ashish |
| description | [...]there are no studies evaluating bleeding risk using triple therapy (including NOACs) vs. [...]we sought to evaluate bleeding risk with triple therapy including NOACs vs. |
| doi_str_mv | 10.1016/S0735-1097(16)30547-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1780673702</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0735109716305472</els_id><sourcerecordid>4020686171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2322-ee2ed8c1940aa507fde461f31a41d2e7035c58f7792cf76d143ff50a8711fadf3</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhSMEEkPhEZAssZlZpPgnjjMbkJW4iYVJRkkGxMqKHFtKGWbapK3U5-IFcSaICjasbN9z7ndtnyB4i-Algih-30BGaIjglq1RvCGQRizEz4IVojQJCd2y58Hqj-Vl8GqariGEcYK2q-BnW8udEoCXrUwrnu-V34G2EDXffQOyTNU-k2UOyuqLUH-7GrAuK542G1_OQLbni75TvBVKPEHWGd-1GyAbwJumSqWXM_BVtgVoZF7KK5n6NnUeVgveeLEQn6u6LnguQC2bT57ESzBTAFdVKV4HL1x3mOyb3-tFsL8SbVqEqso9TIUGE4xDa7HtE4O2Eew6CpnrbRQjR1AXoR5bBgk1NHGMbbFxLO5RRJyjsEsYQq7rHbkI3i3cm_F0e2-nO319uh-PfqRGLIExIwxi76KLy4ynaRqt0zfj8KMbHzWCes5Hn_PR8-drfzrno-e-j0uf9U94GOyoJzPYo7H9MFpzp_vT8F_Ch38I5jAcB9MdvttHOz1dVk9YwwUyM1B8JmDyC392nes</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1780673702</pqid></control><display><type>article</type><title>TRIPLE ANTICOAGULANT THERAPY INCLUDING NOVEL ANTICOAGULANTS (NOACS) AND DUAL ANTIPLATELET THERAPY (DAPT) IS ASSOCIATED WITH SIGNIFICANTLY INCREASED HEMORRHAGE RISK THAN DAPT ALONE</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via ScienceDirect (Elsevier)</source><source>Alma/SFX Local Collection</source><creator>Pattanshetty, Deepak ; Aneja, Ashish</creator><creatorcontrib>Pattanshetty, Deepak ; Aneja, Ashish</creatorcontrib><description>[...]there are no studies evaluating bleeding risk using triple therapy (including NOACs) vs. [...]we sought to evaluate bleeding risk with triple therapy including NOACs vs.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/S0735-1097(16)30547-2</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>Anticoagulants ; Cardiology ; Cardiovascular ; Health risk assessment ; Hemorrhage ; Internal Medicine</subject><ispartof>Journal of the American College of Cardiology, 2016-04, Vol.67 (13), p.546-546</ispartof><rights>American College of Cardiology Foundation</rights><rights>2016 American College of Cardiology Foundation</rights><rights>Copyright Elsevier Limited Apr 5, 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0735-1097(16)30547-2$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Pattanshetty, Deepak</creatorcontrib><creatorcontrib>Aneja, Ashish</creatorcontrib><title>TRIPLE ANTICOAGULANT THERAPY INCLUDING NOVEL ANTICOAGULANTS (NOACS) AND DUAL ANTIPLATELET THERAPY (DAPT) IS ASSOCIATED WITH SIGNIFICANTLY INCREASED HEMORRHAGE RISK THAN DAPT ALONE</title><title>Journal of the American College of Cardiology</title><description>[...]there are no studies evaluating bleeding risk using triple therapy (including NOACs) vs. [...]we sought to evaluate bleeding risk with triple therapy including NOACs vs.</description><subject>Anticoagulants</subject><subject>Cardiology</subject><subject>Cardiovascular</subject><subject>Health risk assessment</subject><subject>Hemorrhage</subject><subject>Internal Medicine</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqFkc1u1DAUhSMEEkPhEZAssZlZpPgnjjMbkJW4iYVJRkkGxMqKHFtKGWbapK3U5-IFcSaICjasbN9z7ndtnyB4i-Algih-30BGaIjglq1RvCGQRizEz4IVojQJCd2y58Hqj-Vl8GqariGEcYK2q-BnW8udEoCXrUwrnu-V34G2EDXffQOyTNU-k2UOyuqLUH-7GrAuK542G1_OQLbni75TvBVKPEHWGd-1GyAbwJumSqWXM_BVtgVoZF7KK5n6NnUeVgveeLEQn6u6LnguQC2bT57ESzBTAFdVKV4HL1x3mOyb3-tFsL8SbVqEqso9TIUGE4xDa7HtE4O2Eew6CpnrbRQjR1AXoR5bBgk1NHGMbbFxLO5RRJyjsEsYQq7rHbkI3i3cm_F0e2-nO319uh-PfqRGLIExIwxi76KLy4ynaRqt0zfj8KMbHzWCes5Hn_PR8-drfzrno-e-j0uf9U94GOyoJzPYo7H9MFpzp_vT8F_Ch38I5jAcB9MdvttHOz1dVk9YwwUyM1B8JmDyC392nes</recordid><startdate>20160405</startdate><enddate>20160405</enddate><creator>Pattanshetty, Deepak</creator><creator>Aneja, Ashish</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20160405</creationdate><title>TRIPLE ANTICOAGULANT THERAPY INCLUDING NOVEL ANTICOAGULANTS (NOACS) AND DUAL ANTIPLATELET THERAPY (DAPT) IS ASSOCIATED WITH SIGNIFICANTLY INCREASED HEMORRHAGE RISK THAN DAPT ALONE</title><author>Pattanshetty, Deepak ; Aneja, Ashish</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2322-ee2ed8c1940aa507fde461f31a41d2e7035c58f7792cf76d143ff50a8711fadf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Anticoagulants</topic><topic>Cardiology</topic><topic>Cardiovascular</topic><topic>Health risk assessment</topic><topic>Hemorrhage</topic><topic>Internal Medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pattanshetty, Deepak</creatorcontrib><creatorcontrib>Aneja, Ashish</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pattanshetty, Deepak</au><au>Aneja, Ashish</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TRIPLE ANTICOAGULANT THERAPY INCLUDING NOVEL ANTICOAGULANTS (NOACS) AND DUAL ANTIPLATELET THERAPY (DAPT) IS ASSOCIATED WITH SIGNIFICANTLY INCREASED HEMORRHAGE RISK THAN DAPT ALONE</atitle><jtitle>Journal of the American College of Cardiology</jtitle><date>2016-04-05</date><risdate>2016</risdate><volume>67</volume><issue>13</issue><spage>546</spage><epage>546</epage><pages>546-546</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><abstract>[...]there are no studies evaluating bleeding risk using triple therapy (including NOACs) vs. [...]we sought to evaluate bleeding risk with triple therapy including NOACs vs.</abstract><cop>New York</cop><pub>Elsevier Inc</pub><doi>10.1016/S0735-1097(16)30547-2</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0735-1097 |
| ispartof | Journal of the American College of Cardiology, 2016-04, Vol.67 (13), p.546-546 |
| issn | 0735-1097 1558-3597 |
| language | eng |
| recordid | cdi_proquest_journals_1780673702 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via ScienceDirect (Elsevier); Alma/SFX Local Collection |
| subjects | Anticoagulants Cardiology Cardiovascular Health risk assessment Hemorrhage Internal Medicine |
| title | TRIPLE ANTICOAGULANT THERAPY INCLUDING NOVEL ANTICOAGULANTS (NOACS) AND DUAL ANTIPLATELET THERAPY (DAPT) IS ASSOCIATED WITH SIGNIFICANTLY INCREASED HEMORRHAGE RISK THAN DAPT ALONE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T01%3A06%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TRIPLE%20ANTICOAGULANT%20THERAPY%20INCLUDING%20NOVEL%20ANTICOAGULANTS%20(NOACS)%20AND%20DUAL%20ANTIPLATELET%20THERAPY%20(DAPT)%20IS%20ASSOCIATED%20WITH%20SIGNIFICANTLY%20INCREASED%20HEMORRHAGE%20RISK%20THAN%20DAPT%20ALONE&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Pattanshetty,%20Deepak&rft.date=2016-04-05&rft.volume=67&rft.issue=13&rft.spage=546&rft.epage=546&rft.pages=546-546&rft.issn=0735-1097&rft.eissn=1558-3597&rft_id=info:doi/10.1016/S0735-1097(16)30547-2&rft_dat=%3Cproquest_cross%3E4020686171%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1780673702&rft_id=info:pmid/&rft_els_id=S0735109716305472&rfr_iscdi=true |